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nonsyndromic CP and is one of few functional variants identified to date for nonsyndromic orofacial clefting. This finding advances
our understanding of the genetic basis of craniofacial development and might ultimately lead to improvements in recurrence risk pre-
diction, treatment, and prognosis.Introduction
Orofacial clefts (OFCs [MIM: 119530]) comprise any
developmentally arising cleft, i.e., disruption or gap, in
orofacial structures including the lips, palate, eyes, and
nose.1 Of these, cleft lip (CL), cleft palate (CP), and cleft
lip with cleft palate (CLP) are among the most common
birth defects in humans with prevalence between 1 in
500 and 1 in 2,500 live births.2 Because other types of
OFCs are exceedingly rare, we will use OFCs here to
describe the subset affecting only the lip and palate
(i.e., CL, CLP, and CP).
OFCs arise from failure of normal craniofacial develop-
mental processes that requires coordinated cell growth,
migration, differentiation, and apoptosis.3 The upper lip
develops during the 4th–7th weeks of embryogenesis from
several events culminating in the growth, migration, and
fusion of the medial and lateral nasal processes with the
maxillary processes. Disruption of any of these events re-
sults in CL. Development of the secondary palate begins
in the 7th week of embryogenesis when the palatal shelves
emerge from the maxillary processes. Growth and eleva-
tion of the palatal shelves followed by fusion at the
midline results in a complete separation of the nasal and
oral cavities. Failure of any of these steps can lead to CP.
Because of the distinct developmental origins of the lip
and palate, OFCs are commonly divided into CL with or
without CP (CL/P, i.e., CL and CLP) and CP.4,5
In addition, OFCs are further divided into two classes—
syndromic and nonsyndromic—for the purposes of clin-
ical diagnosis, recurrence risk predictions, and identifica-
tion of etiologies. Approximately 70%–80% of CL/P and
50% of CP6 are considered nonsyndromic based on the
absence of additional structural or cognitive abnormalities.
There is now convincing evidence that nonsyndromic
OFCs represent complex human disorders with genetic
risk factors, environmental exposures, and their interac-
tions, all contributing to susceptibility.
Although a number of the genes in which mutations
cause syndromic CP have been elucidated,7 few have
been identified for nonsyndromic CP (MIM: 119540).
One gene that might influence risk for CP is FAF1 (MIM:
604460), which was initially identified from a transloca-
tion in a multiplex CP-affected family with Pierre Robin
sequence (MIM: 261800).8 Subsequently, SNPs near FAF1
were shown to be associated with nonsyndromic CP in
trios of European ancestry.8 However, the FAF1 locus
only partially accounts for the heritability of CP, and there-
fore, we hypothesize that other risk loci exist. Whereas five
GWASs of CL/P have identified at least 15 genetic loci with
compelling statistical support,9 only one GWAS for CP has
been completed with no statistically significant SNP main
effects for FAF1 or any other gene.10 Insufficient sampleThe Amsizes for genomic studies could account for the paucity of
gene discovery for CP. However, several significant gene-
environment interaction effects were observed upon inclu-
sion of maternal smoking, alcohol, or vitamin exposures.10
Moreover, many of the CL/P risk factors identified to date
have also been studied in CP cohorts with mixed results,
suggesting differences in the underlying genetic etiology.
For example, SNPs from the four European CL/P-associated
loci (1q32, 8q24, 10q25, and 17q22) were tested in CP trios
but were not significantly associated.11 Additional CL/P
SNPs were tested for association with submucous CP, but
again were not significantly associated.12 However, other
candidate gene studies have shown association with both
CL/P and CP including a SNP within microRNA-140
(MIM: 611894)13 and SNPs near FOXE1 (MIM: 602617).14
Overall there seems to be little overlap between loci associ-
ated with CL/P and the few loci associated with CP to date,
supporting the notion that CL/P and CP largely have
distinct genetic etiologies.
Here we report the results of a GWAS of nonsyndromic
CP in a multiethnic sample. We identified a genome-
wide significant association with nonsyndromic CP: a
missense variant in GRHL3 (MIM: 608317) significantly
associated in case subjects of European ancestry and
independently replicated. We further examined this
variant in a zebrafish model and cell-based transactivation
assays and conclude that it is an etiologic variant for non-
syndromic CP.Subjects and Methods
Discovery Sample Description
Our current study was part of a collaborative effort to investigate
the genetic basis of orofacial clefts in participants recruited from
13 countries across five continents. Most of the sites were part of
ongoing studies led by the University of Pittsburgh Center for
Craniofacial and Dental Genetics and the University of Iowa.
Recruitment and study assessments were done at regional OFC
treatment centers. Informed consent was obtained for all partici-
pants and all sites had both local IRB approval and approval at
the University of Pittsburgh or the University of Iowa. The affec-
tion status for the current study was cleft palate (CP), defined as
any disruption of the hard and/or soft palate, including submu-
cous CP. The discovery study sample consisted of two independent
subsets: (1) a set of 165 unrelated case-parent trios and (2) 78 un-
related CP case subjects and 1,700 unrelated control subjects with
no family history of craniofacial birth defects (Table S1).
Genotyping and Quality Control
Participants were genotyped for approximately 580,000 SNPs on
an Illumina HumanCoreExome array plus 15,890 SNPs of custom
content designed to cover candidate genes and loci implicated by
previous genome-wide or candidate gene studies or from animal
models with craniofacial anomalies. Genetic data were extensivelyerican Journal of Human Genetics 98, 744–754, April 7, 2016 745
cleaned and quality checked via standard analysis pipelines devel-
oped by the Genetics Coordinating Center (GCC) at the Univer-
sity of Washington.15 These analyses included interrogation of
samples for unexpected duplicates, genetic sex, chromosomal
anomalies, familial relatedness, population structure, missing-
ness, batch effects, duplicate sample discordance, and Mendelian
errors among relatives. The quality of SNP probes was examined
by inter-sample comparisons (i.e., concordance across sample du-
plicates and HapMap controls, Mendelian errors, etc.), missing
call rates, deviations from Hardy-Weinberg equilibrium (in a
genetically defined homogenous subset of European partici-
pants), concordance across duplicate probes, and separation of
clusters during genotype calling. A total of 539,473 SNPs
(comprising 96.74% of those attempted) passed quality filters
(see Table S3). Of these, 293,633 SNPs had minor allele fre-
quencies of 1% or greater. Principal-component analysis (PCA)-
based methods were used to assess ancestry and assign
participants into four genetic analysis groups reflecting continen-
tal origin: Europe, Asia, Africa, and Central/South America. Geno-
types and phenotypes for this project are available on dbGaP.
Further details regarding the quality assurance, ancestry analyses,
imputation, and data cleaning efforts are available in the Quality
Control Report issued by the University of Washington GCC for
our project, available online. Results can be browsed as part of the
Facebase Consortium’s Human Genomics Analysis Interface (see
Web Resources).Imputation
Prior to imputation of unobserved genetic polymorphisms, SNPs
passing quality filters were ‘‘pre-phased’’ to create haplotypes us-
ing SHAPEIT2.16 Imputation was conducted using IMPUTE217
and phase 3 of the 1000 Genomes Project (comprising 2,504 indi-
viduals from 26 populations worldwide) as the reference panel.
Genotype data for a total of 34,985,077 SNPs were available after
imputation, including both fully imputed SNPs as well as geno-
typed SNPs for which sporadic missingness was imputed. Masked
variant analysis, whereby genotyped SNPs were imputed in order
to assess imputation accuracy, demonstrated high-quality imputa-
tion, with mean concordance of 0.995 for SNPs with minor allele
frequency (MAF)< 0.05 and 0.960 for SNPs withMAFR 0.05. The
‘‘most-likely’’ genotypes (i.e., genotypes with the highest probabil-
ity [Q]) were selected for statistical analysis only if the genotype
with the highest probability was greater than 0.5. Imputed SNPs
with deviations from Hardy-Weinberg equilibrium were filtered
out of downstream analyses.Statistical Analyses
The European GWAS data were analyzed in the case-control subset
using logistic regression while adjusting for five PCs of ancestry
(defined in the European ancestry group), and in the trio subset
via the transmission disequilibrium test (TDT).18 Both the TDT
and logistic regression analyses were performed as implemented
in PLINK.19 Association results for the two GWAS scans were com-
bined by weighted odds ratio meta-analysis20 to estimate our
study-wide association results. We extended the GWAS approach
to the full multiethnic sample using the same two-stage approach.
For the multiethnic GWAS, 18 PCs of ancestry were included in
the logistic regression model to account for population structure.
Note, due to small sample sizes, stratified analyses were not per-
formed individually in the Asian, Central/South American, or
African groups.746 The American Journal of Human Genetics 98, 744–754, April 7, 2Replication Sample and Genotyping
Samples utilized for replication genotyping came from five popu-
lation-based OFC case-control studies (two American and three
European): the Danish National Birth Cohort (DNBC),21 the
Iowa Case-Control Study (Iowa),22 the Norway Facial Clefts Study
(NCL),23 the Norwegian Mother and Child Cohort (MoBa),24 and
the Utah Child and Family Health Study (Utah)25 (see Table S2).
Case and control subjects were identified primarily through na-
tional or state-based birth registries. Seven SNPs from three loci
were genotyped using TaqMan SNP Genotyping Assays (Life Tech-
nologies) on the Fluidigm microfluidic EP1 SNP Genotyping Sys-
tem and GT192.24 Dynamic Array Integrated Fluidic Circuits
(IFCs) (Fluidigm). Statistical analysis was performed using logistic
regression, for case versus control status for each SNP, one at a
time, controlling for study site.
A second, in silico, replication sample came from the GENEVA
International Cleft Consortium, which previously published
GWASs of CL/P and CP.10,26 A total of 468 CP case-parent trios
of varied ancestry were used from sites across the US, Europe,
and Southeast and East Asia. Samples were genotyped on the
Illumina Human610-Quad platform and imputed by the
GENEVA Coordinating Center using the IMPUTE2 software and
the 1000 Genomes Project reference panel (June 2011 release).
Statistical analysis was performed with TDT, implemented in
PLINK.
Sanger Sequencing
Sanger sequencingwas performed using primers andmethodology
as previously described27 on 84 independent case subjects with CP
recruited at the University of Iowa. PCR products were sent for
sequencing on an ABI 3730XL (Functional Biosciences). Chro-
matograms were transferred to a UNIX workstation, base-called
with PHRED (v.0.961028), assembled with PHRAP (v.0.960731),
scanned by POLYPHRED (v.0.970312), and viewed with the
CONSED program (v.4.0). Variants were compared with the
Exome Aggregation Consortium browser.
Functional Test of Human GRHL3 Mutation Variants
in Zebrafish Embryos
Full-length, wild-type human GRHL3 cDNA (GenBank:
BC036890.2) was obtained from GE Healthcare. The p.Thr454Met
(c.1361C>T), p.Val160Ala (c.479T>C), and p.Asn484Ser
(c.1451A>G) substitutions were introduced using PCR-mediated
mutagenesis.28 cDNA coding wild-type, p.Thr454Met, p.Val160Ala,
and p.Asn484Ser GRHL3 were shuttled into CS2þ vector and the
corresponding capped mRNAs were generated in vitro with
mMESSAGEmMACHINESP6kit (Ambion)andpurifiedwithRNeasy
mini kit (QIAGEN). After injecting a range of quantities of mRNA,
itwas determined that embryos tolerated1ngof lacZmRNAwithout
a significant reduction in survival. Approximately 1 ng of mRNA
was injected into wild-type zebrafish embryos (inbred from NHGRI
line) at the 1-cell stage.29 Embryos were fixed at 6 hpf and whole-
mount in situ hybridization for krt4 was performed as described
previously.30 Animal use protocols were approved by the Public
Health Service Assurance.
Luciferase Reporter Constructs, Electroporation, and
Luciferase Assays
For test of the function of different GRHL3 variants, a syn-
thetic GRHL3-sensitive enhancer was generated by synthesizing
an oligonucleotide containing four replicates of the GRHL3016
Table 1. Top Hits from GWAS of Cleft Palate
Locus SNP Analysis
European Ancestry Combined Multi-ethnic Sample
OR [99.999995% CI] p Value OR [99.999995% CI] p Value
1p36 (GRHL3) rs41268753 CC 8.3 (1.17,59.15) 4.08 3 109 6.3 (1.04,38.86) 2.75 3 108
TDT 1.4 (0.058,34.07) 0.56 2.0 (0.13,30.53) 0.15
Meta 5.1 (0.96, 27.13) 1.10 3 107 4.5 (0.98,20.14) 6.90 3 108
6p26 (PARK2) rs12175475 CC 7.4 (0.77,71.21) 1.42 3 106 6.6 (1.12,39.58) 8.66 3 109
TDT 1.0 (0.032,31.43) 1.00 1.3 (0.08,20.07) 0.61
Meta 4.1 (0.61,26.88) 5.55 3 105 4.1 (0.91,18.18) 5.39 3 106
11q22.1 (YAP1) rs117496742 CC 11.2 (1.04,121.8) 3.13 3 108 9.2 (0.91,92.28) 1.64 3 107
TDT 2.0 (0.04,94.42) 0.31 2.0 (0.04,94.42) 0.31





and engineered into pTol2-cFos-FLuc. pTol2-cFos-FLuc was engi-
neered from pT2cfosGW,32 by replacing the GFP gene with FLuc.
For electroporation in human oral epithelial cell line, GMSM-K33
was electroporated with Amaxa Cell Line Nucleofector Kit V
(LONZA) in Nucleofector II Device (Program: X-005) (LONZA).
For dual luciferase assay, GMSM-K was co-electroporated with
empty CS2þ plasmids (Gift of David Turner, U. Michigan), wild-
type or different GRHL3 mutation variants overexpression plas-
mids, along with GRHL3-sensitive reporter described above. The
Dual-luciferase Reporter Assay System (Promega) and a luminom-
eter were used to measure luciferase activity in cell lysates 4 days
after transfection. All quantified results are presented as mean 5
SEM. Three luciferase measurements were made on each of three
independent biological replicates. A two-tailed unpaired Student’s
t test was used to determine statistical significance.Results
GWAS of Nonsyndromic CP
We performed a GWAS in two independent subsets from
a sample of nonsyndromic CP of European ancestry
(Table 1). The first was a set of 38 unrelated case subjects
and 835 unrelated control subjects and the second was a
set of 93 unrelated case-parent trios (Table S1). A total of
455,449 genotyped SNPs and 33,669,354 imputed SNPs
were analyzed separately in each subset and combined by
meta-analysis (Figure 1). We observed significant associa-
tions in the case-control scan on chromosome 1 spanning
GRHL3 and nearby genes (Figures 1A and 2A; lead SNP
rs41268753; p ¼ 4.08 3 109) and on chromosome 11
near YAP1 ([MIM: 606608]; Figure S1; rs117496742;
p ¼ 3.13 3 108). No significant associations were
observed in the European TDT (Figure 1B). Both GRHL3
and YAP1 showed suggestive associations in a meta-anal-
ysis of European case-control and TDT scans (Figure 1C;
p values ¼ 6.90 3 108 and 5.88 3 107, respectively).The AmTables S4–S6 contain results for all genotyped SNPs
yielding p values less than 1.0 3 105 in the European
case-control, TDT, and meta-analyses, respectively.
We next conducted a GWAS in a larger multiethnic sam-
ple of nonsyndromic CP by adding 40 unrelated case sub-
jects, 865 unrelated control subjects, and 75 trios from
Asian, African, and Central/South American continental
groups to the European participants studied above
(Table S1). A total of 78 unrelated cases, 1,700 unrelated
controls, and 165 trios were analyzed using the same
statistical approaches. As with the European sample anal-
ysis, statistically significant associations were observed
in the multiethnic sample case-control analysis (Fig-
ure S2A). rs41268753 (GRHL3) again showed association,
although the statistical significance was slightly decreased
(p value ¼ 2.75 3 108), indicating that this signal was
driven by the European sample. We also observed a second
locus within PARK2 (MIM: 602544) on chromosome 6
(Figure S3; lead SNP rs12175475; p value ¼ 8.66 3 109).
No significant associations were observed in the multi-
ethnic trio scan (Figure S2B), whereas the multiethnic
meta-analysis showed an association for the GRHL3 locus
(Figure S2C; lead SNP rs113965554; p value ¼ 5.03 3
108), with rs41268753 showing suggestive evidence of as-
sociation (p value ¼ 6.90 3 108). Tables S7–S9 contain re-
sults for all genotyped SNPs yielding p values less than
1.0 3 105 in the multiethnic case-control, TDT, and
meta-analysis scans.
Replication
We selected seven SNPs (two SNPs each for GRHL3 and
YAP1, three SNPs for PARK2) for replication and genotyped
each in 246 unrelated case subjects and 1,685 unrelated
control subjects from population-based samples of Euro-
pean ancestry (Table 2; for description of the replication
cohort see Table S2). Both GRHL3 SNPs (rs41268753 and
rs113965554) showed evidence of replication (p ¼ 2.8 3
104 and p ¼ 6.8 3 104, respectively). We also performed
in silico replication analyses in the cohort from the
previously published GWAS of nonsyndromic CP in theerican Journal of Human Genetics 98, 744–754, April 7, 2016 747
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Figure 1. Manhattan Plots of –log10(p
Values) from a European CP Cohort
Results are shown for (A) logistic regression
of 38 case subjects and 835 control sub-
jects, (B) TDT in 93 trios, and (C) meta-
analysis of case-control and TDT results.
Colored lines denote suggestive (blue)
and genome-wide (red) thresholds for sig-
nificance. The genomic inflation factor, ʎ,
was 0.934, 1.018, and 0.926 for the case-
control, trio, and meta-analysis scans,
respectively, indicating negligible inflation
of p values.GENEVA Oral Clefts Consortium.10 The SNPs we selected
for replication were not among the genotyped SNPs
included in the published study; two of the seven SNPs
(GRHL3 SNPs rs41268753 and rs113965554) were success-
fully imputed using the 1000 Genomes reference panel,
and both showed evidence of association (p ¼ 7.6 3 103
and p ¼ 6.8 3 104, respectively; Table 2). Note that the
GENEVA Oral Clefts Consortium included some of the
same participants as the discovery sample, so we removed
overlapping participants and re-ran analyses. After
removal of overlapping individuals, evidence of replica-
tion remained (p ¼ 0.016 and p ¼ 1.5 3 103 for
rs41268753 and rs113965554, respectively).
rs41268753 Is a Missense Variant in GRHL3 that
Increases Risk for CP
The risk allele for rs41268753 (GRHL3) results in an
amino acid residue change (GenBank: NM_198173,
NP_937816.1; c.1361C>T [p.Thr454Met]) in exon 11 of
GRHL3. The minor allele frequency of rs41268753 among
European controls was 2.75%, consistent with the 3.06%
frequency reported in non-Finnish European populations
in the ExAC database. However, among our European CP
discovery case subjects, the MAF of rs41268753 was
19.74%, resulting in an 8.3-fold increased risk of CP un-
der an additive model (OR ¼ 8.31 [95% CI: 4.1–16.8;
genome-wide 99.999995% CI: 1.17–59.15]). In contrast,
the OR point estimates were more modest in the
replication samples (ORcase-control ¼ 2.16 [1.43–3.27];
ORGENEVA ¼ 2.4 [1.48–5.019]). Although we did not
detect an association with rs41268753 in the TDT anal-748 The American Journal of Human Genetics 98, 744–754, April 7, 2016ysis, the frequency was elevated in
the affected probands of the trios




Nonsyndromic CP Case Subjects
We previously found that rare, domi-
nant mutations in GRHL3 cause Van
der Woude syndrome (VWS [MIM:
119300, 606713]), the most common
syndromic cause of OFC, and weresignificantly more frequent among individuals with
VWS who had CP27 as opposed to other forms of OFC.
In addition, we previously found that families with
GRHL3 mutations were significantly less likely to have
lower lip pits, one of the defining features of VWS that
occur in 85% of VWS cases. Based on these results, we
hypothesized that dominant coding variants could be
found in apparently nonsyndromic CP case subjects. We
therefore explored GRHL3 variation in CP samples by
Sanger sequencing GRHL3 exons in an independent set
of 84 case subjects of European, Asian, or mixed
ancestries. In these 84 case subjects, we detected only
two missense variants not found in dbSNP137. The
first (GenBank: NM_198173.2, NP_937816.1; c.892C>T
[p.Arg298Cys]) was found in an individual with no
family history of CP (Figure S4) and was also present in
two individuals in the ExAC database. The second
missense variant (GenBank: NM_198173.2, NP_937816.
1; c.1640A>C [p.Lys547Thr]), was found in an individual
in an apparently dominant pedigree with three consecu-
tive generations with CP. However, the variant did not
segregate with CP in the family and is unlikely to be path-
ogenic (Figure S4). In the 54 individuals reporting Euro-
pean ancestry, we found rs41268753 at a frequency of
10.4%, which is consistent with the frequencies of the
variant among CP case subjects in our discovery and
replication samples. Although it is possible that some in-
dividuals with apparently nonsyndromic CP could have
coding variants such as those we previously reported in
VWS, these results suggest that this is not a common
occurrence.
AB
Figure 2. GRHL3 Is Associated with Non-
syndromic CP
(A) Regional association plot34 showing
–log10(p values) for genotyped (filled
squares) and imputed (open circles) SNPs
for the 1p36 locus nearGRHL3. The recom-
bination overlay (blue line, right y axis) in-
dicates the boundaries of the LD-block.
Points are color coded according to pair-
wise linkage disequilibrium (r2) with the
index SNP, rs41267835.
(B) Schematic representation of GRHL3
(GenBank: NM_198173). Exons are colored
according to the three known protein
domains: the transactivation (green),
the DNA binding (orange), and the dimer-
ization (light blue) domains. The posi-
tion of each of the variants tested in
zebrafish assays are indicated and
described at the nucleotide and protein
level. rs41268753 (p.Thr454Met) (red)
is associated with CP in the current
study; rs34637004 (p.Val160Ala) and
rs116396279 (p.Asn484Ser) (navy) were
not associated with CP; and p.Arg391Cys
(salmon) is a mutation previously reported
to cause Van der Woude syndrome.27Functional Analysis of rs41268753
In our previous work, we tested the activity of GRHL3
protein variants detected in VWS-affected families by in-
jecting synthetic mRNA encoding them into single-cell
zebrafish embryos.27 At late blastula stage (5 hr post fertil-
ization [hpf]), embryos injected with wild-type human
GRHL3 mRNA exhibited ectopic expression of krt4, a
marker of the most superficial cell layer (the periderm),
in deep blastomeres. In contrast, ectopic krt4 expression
was absent in embryos injected with themRNA containing
GRHL3 mutations detected in VWS-affected families.
Further, such embryos exhibited loss of endogenous krt4
expression in the periderm and ruptured through the
animal pole at around 6 hpf, consistent with a failure of
periderm differentiation.27,30 These results signify that in
zebrafish embryos, GRHL3 variants detected in VWS-
affected families lack transactivation activity and appear
to have the potential to interfere with the activity of
endogenous Grhl3.
Here, we utilized the same in vivo zebrafish assay to
determine whether p.Thr454Met (rs41268753) alters the
function of GRHL3.27,35 Because common variants associ-
ated with disease are expected to have a smaller effect size
compared to those mutations causing Mendelian dis-
eases,36 we anticipated that the common p.Thr454Met
variant would have lower-than-wild-type ability to
induce ectopic krt4 but would less efficiently disrupt peri-The American Journal of Humaderm development than the rare mu-
tations previously identified in VWS-
affected families (e.g., p.Arg391Cys
[c.1171C>T]). We further anticipated
that two other coding polymor-phisms that are not associated with CP would have
wild-type activity in these assays; we selected two such
variants (rs116396279 [p.Asn484Ser] and rs34637004
[p.Val160Ala]) that were not associated with CP in our
GWAS (p > 0.2).
We engineered full-length GRHL3 cDNA to encode each
of these variants (depicted in Figure 2B), synthesized
mRNA in vitro from each construct, and injected it into
wild-type zebrafish embryos at the 1- to 2-cell stage. At
shield stage (6 hpf), a majority of embryos injected with
mRNA encoding beta-galactosidase (as a negative control)
(Figures 3A and 3E), wild-type GRHL3 (Figures 3B and
3E), p.Asn484Ser GRHL3 (Figures 3C and 3E), and
p.Val160Ala GRHL3 (not shown) all developed normally,
except for a slight delay in epiboly, and only a few had
ruptured. In contrast, virtually all embryos injected with
mRNA encoding the p.Arg391Cys VWS variant had
ruptured by 6 hpf (Figure 3E), consistent with our earlier
observations.27 The majority of embryos injected with
mRNA encoding p.Thr454Met GRHL3 remained intact at
6 hpf, although they appeared to have stalled at mid-epib-
oly stage; by 8 hpf, however, virtually all had ruptured (Fig-
ures 3D and 3E). We repeated the injections, fixed embryos
at 5 hpf, and processed embryos to reveal expression of krt4
mRNA. As expected, embryos injected with mRNA encod-
ing wild-type GRHL3 (Figure S5B) and p.Val160Ala (Fig-
ure S5C) and p.Asn484Ser (Figure S5D) GRHL3 exhibitedn Genetics 98, 744–754, April 7, 2016 749
Table 2. Results of Genetic Association in the Replication Cohort
of 246 Case Subjects and 1,685 Unrelated Control Subjects for 7
SNPs in Loci Observed in the Discovery GWAS
Locus SNP
Minor
Allele p Value OR 95% CI
1p36
(GRHL3)
rs41268753 T 2.81 3 104 2.16 1.43–3.27
rs113965554 A 6.82 3 104 1.97 1.33–2.91
6p26
(PARK2)
rs12175475 T 0.97 0.99 0.52–1.87
rs9347594 T 0.97 1.00 0.82–1.21
rs9365380 T 0.91 1.01 0.83–1.23
11q22.1
(YAP1)
rs11225351 T 0.81 1.03 0.83–1.28
rs117496742 A 0.20 0.60 0.27–1.31
Figure 3. p.Thr454Met, a CP-Associated Variant of GRHL3, Dis-
rupts Development of Periderm upon Overexpression in Zebra-
fish Embryos
(A–D) Lateral views of live embryos derived from a single clutch at
about 8 hpf, injected at the 1- to 2-cell stage withmRNAs encoding
the indicated proteins. Asterisks (in D) indicate rupturing em-
bryos. Scale bars represent 250 mm.
(E) Bar chart representing percentage of embryos, from 3 experi-
ments of at least 40 embryos each, that ruptured after injection
of mRNA encoding the indicated protein. Error bars indicate stan-
dard error.
(F) Bar chart representing normalized luciferase levels in GMSM-K
oral epithelium cells co-electroporated with the indicated amount
(in mg) of the indicated plasmids. Abbreviations are as follows:
FFLuc, empty firefly luciferase vector; GMFFLuc, multimerized
GRHL3 binding site in firefly luciferase vector; CS2þ, empty
plasmid used to make overexpression constructs; GRHL3, wild-
type; p.Arg391Cys; a GRHL3 variant identified in a family with
Van der Woude syndrome;27 p.Thr454Met, a GRHL3 variant asso-
ciated with CP in the present study. Luciferase signal is the ratio of
firefly and renilla luciferase measurements, normalized to the
signal in empty firefly transfection group (FFLuc). The data repre-
sent results from three separate experiments, and error bars repre-
sent standard error. Asterisk indicates p < 0.05.intense ectopic krt4 expression in deep cells; endogenous
krt4 expression in periderm was present, further confirm-
ing that the p.Val160Ala and p.Asn484Ser variants are
indistinguishable from wild-type GRHL3 in this assay.
A minority of embryos injected with mRNA encoding
p.Thr454Met GRHL3 exhibited small patches of low-level
ectopic krt4 expression (not shown), whereas the majority
had large patches of superficial cells lacking endogenous
krt4 expression (Figure S5E).
We also examined the ability of p.Thr454Met and
p.Arg391Cys, alone or together with wild-type GRHL3, to
activate reporter expression in vitro. We engineered four
replicates of a consensus GRHL3 binding motif31 into a
luciferase reporter vector and electroporated this construct
together with GRHL3 expression plasmids into an oral ker-
atinocyte cell line (GMSM-K). In cells transfected with
cDNA encoding wild-type GRHL3, the level of reporter
activity was 80-fold higher than in cells transfected with
an empty expression plasmid (control-transfected cells)
(Figure 3F). In cells transfected with cDNA encoding
p.Arg391Cys GRHL3, the level of reporter activity was
lower than in control-transfected cells (Figure 3F). By
contrast, in cells transfected with cDNA encoding
p.Thr454Met GRHL3, the level of reporter activity was
about 30-fold higher than in control cells (Figure 3F). In
cells cotransfected with equal amounts of cDNA encoding
wild-type GRHL3 and either p.Arg391Cys GRHL3 or
p.Thr454Met GRHL3 variants, the level of reporter activity
was intermediate between the levels in cells transfected
with either variant alone (Figure 3F). In summary, whereas
the VWS-associated p.Arg391Cys variant lacks transactiva-
tion activity, the CP-associated p.Thr454Met variant re-
tains about four-tenths normal activity. Both variants
have the ability to interact with GRHL3, presumably by
forming dimers with it, lessening its transactivation
activity.Discussion
GRHL3 encodes a transcription factor in the grainy-head
family with multiple conserved roles in developmental750 The American Journal of Human Genetics 98, 744–754, April 7, 2processes including neural tube closure,37 epidermal
barrier formation,38 wound healing,39 and craniofacial
development.27,40 In zebrafish, embryos injected with
morpholinos targeting grhl3 exhibit craniofacial hypopla-
sia,40 while those injected simultaneously with morpholi-
nos targeting grhl3 and grhl1, or those injected with
RNA encoding Grhl1 DNA binding domain, expected to
block function of both orthologs, rupture and die during016
gastrulation with loss of periderm markers.35 Analysis of
grhl3 mutants has not been reported. In mouse, loss
of Grhl3 results in oral adhesions and aberrant elevation
of the palatal shelves, leading to cleft palate.27 In both or-
ganisms, Grhl3 is required for development of the peri-
derm, Grhl3 acting downstream of Irf635 in zebrafish, but
no genetic interaction between Irf6 and Grhl3 was
observed in mouse.35 Dominant mutations in GRHL3
and IRF6 cause VWS, the most common Mendelian OFC
syndrome.27,41
VWS is characterized by OFCs and lower lip pits but has
considerable variable expressivity (see GeneReviews in
Web Resources). Because 12%–15% of individuals with
VWS present with isolated OFCs, VWS was hypothesized
to serve as a clinical model for nonsyndromic OFCs.42 Mu-
tations in IRF6 (MIM: 607199) were discovered to be one of
the causes of VWS in 200241 and its locus on 1q32 was sub-
sequently implicated in nonsyndromic CL/P in studies
using linkage analysis, candidate gene, and GWAS ap-
proaches.9,43 The recent discovery of GRHL3 mutations
as a second cause of VWS established genetically deter-
mined subclasses.27 We reported that whereas VWS-
affected individuals carrying IRF6 mutations are most
likely to have CL/P and lip pits, those carrying GRHL3mu-
tations are more likely to have CP and less likely to have lip
pits,27 leading to the hypothesis that genetic variation at
this locus also confers risk for nonsyndromic CP.
The association of CP with rs41268753 suggested three
possible identities of the etiologic variant(s) at this locus:
(1) rs41268753 is the etiologic variant; (2) the etiologic
variant is an unobserved common variant in linkage
disequilibrium with rs41268753; or (3) rs41268753 tags a
common haplotype carrying a burden of incompletely
penetrant GRHL3 mutations, such as those found in
VWS. In vitro luciferase assays and in vivo zebrafish exper-
iments allowed us to determine that rs41268753 disrupts
the normal transcriptional activation function of GRHL3
and is a likely etiologic variant for CP in humans. Further-
more, Sanger sequencing of 84 additional CP case subjects
revealed only one novel coding variant, so it is unlikely
that rs41268753 is a surrogate for a burden of private mu-
tations. However, we acknowledge that this study included
a small number of CP case subjects and we cannot exclude
the possibility that some fraction of individuals with non-
syndromic CP will have dominant GRHL3 mutations. We
recently estimated the frequency of such variants in IRF6
to be ~0.3% based on sequencing of 2,472 CL/P case sub-
jects.44 Similar studies for CP are required to completely
characterize the spectrum of GRHL3 variants.
By identifying an association between the GRHL3 locus
and nonsyndromic CP, our present study extends the
genotype-phenotype correlation observed in VWS to non-
syndromic OFCs. In short, in both syndromic and nonsyn-
dromic OFCs, IRF6 variants underlie risk for CL/P and
GRHL3 variants do so for CP. Ostensibly, it extends a
simplistic paradigm in which damaging mutations with
large effects cause Mendelian disorders whereas lessThe Amdamaging coding variants (e.g., hypomorphic or inhibi-
tory) or regulatory polymorphisms confer risk of common
forms of the same disorder.45,46 However, it is clear that the
relationship between genotype and phenotype at the
GRHL3 locus is not so simplistic. In our previous work,
we demonstrated that dominant GRHL3 mutations cause
VWS. However, these mutations are incompletely pene-
trant; 10% of individuals with mutations were asymptom-
atic and 46% presented with apparently isolated OFCs.
Although these individuals did not have lower lip pits, it
remains possible that future generations might present
with this characteristic feature of VWS.
Whereas the families with rare coding mutations have
dominant inheritance patterns with some nonpenetrance,
the nonsyndromic CP-affected families with rs41268753
have sporadic occurrences of CP and many of the individ-
uals with the risk allele are unaffected. This is consistent
with the results of the functional assays that indicated
both the CP-associated p.Thr454Met variant and the
VWS-associated p.Arg391Cys variant have an inhibitory
effect on wild-type GRHL3, but that the p.Thr454Met
variant appears to be comparatively less disruptive.
Moreover, in contrast to the p.Arg391Cys variant, the
p.Thr454Met variant retains about 40% of normal transac-
tivation activity. It is noteworthy that although each
minor allele of rs41268753 elevates ones’ risk of CP, the
homozygous condition is nonetheless compatible with
life, as shown by the fact that 48 homozygotes for the
risk allele are documented in the ExAC database and
several in our study population. We also note that OFCs
might not have been an exclusion criterion for the studies
contributing to ExAC and that 0.04%–0.2%, or 24–120 of
the 60,706 individuals in ExAC, might have an OFC. The
effects of both rare VWS mutations and rs41268753 are
likely to be modified by the presence of other genetic risk
factors, environmental exposures, epigenetic marks, or sto-
chastic events, leading to the wide spectrum of OFC affec-
tion severity present in study subjects and the general
population.
We employed a two-stage study design consisting of case
and control subjects and case-parent trios, which were
analyzed separately and combined by meta-analysis. How-
ever, our significant results were limited to the case-control
arm of the study. This was probably due to the small num-
ber of trios and the relatively low MAF of associated SNPs.
The risk allele at rs41268753, which occurs at a frequency
of 3% in populations of European ancestry, is extremely
rare or absent in non-European populations and thus un-
likely to account for much of their genetic variance in
CP. In fact, the frequency of CP across different popula-
tions is less variable than for CL/P, so we would predict
fewer such population-specific signals for CP than have
been observed for CL/P.26,47,48 Small sample sizes might
have also contributed to our failure to replicate a previ-
ously reported association with FAF1.8 In multiple cohorts
of European ancestry, the TT genotype of rs1149795 (near
FAF1) was associated with a 1.47-fold increased risk of CP.erican Journal of Human Genetics 98, 744–754, April 7, 2016 751
However, our present study was insufficiently powered to
detect associations with modest effect. Larger sample sizes
of multiple ancestral groups will be required to more
comprehensively identify the common CP risk alleles.
In summary, we performed a GWAS of nonsyndromic CP
and identified and independently replicated an association
between rs41268753 and this common congenital malfor-
mation. Moreover, we demonstrated that this variant
impairs GRHL3 function and periderm development in ze-
brafish and is likely to be the etiologic variant for this CP
risk locus. This is one of few associations observed via
GWASs to occur in the coding region of a gene and one
of few examples of functional variants identified to date
for nonsyndromic OFCs.46,49Accession Numbers
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